US2014107164A1PendingUtilityA1

Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Assignee: TARGACEPT INCPriority: Mar 5, 2003Filed: Dec 17, 2013Published: Apr 17, 2014
Est. expiryMar 5, 2023(expired)· nominal 20-yr term from priority
A61P 31/18A61P 43/00A61P 37/02A61P 9/10A61P 25/00A61P 25/18A61P 25/14A61P 25/34A61P 25/28A61P 25/22A61P 25/30A61P 25/04A61P 25/16A61P 25/08A61P 29/00A61P 25/20A61P 25/02A61P 25/24A61P 21/04A61P 1/00A61P 1/12A61P 21/02A61P 1/04C07D 405/14A61K 31/506C07D 401/06C07D 403/06C07D 405/12
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating gastrointestinal disorders, comprising administering a compound 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The method of  claim 1 , wherein the gastrointestinal disorder is Crohn's Disease, Irritable Bowel Syndrome, or Ulcerative Colitis.

Join the waitlist — get patent alerts

Track US2014107164A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.